Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
88 hedge funds and large institutions have $143M invested in Antares Pharma, Inc. in 2015 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 49 increasing their positions, 13 reducing their positions, and 7 closing their positions.
443% more call options, than puts
Call options by funds: $581K | Put options by funds: $107K
277% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 13
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
13% more capital invested
Capital invested by funds: $127M → $143M (+$16.5M)
9% more funds holding
Funds holding: 81 → 88 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$15.3M |
| 2 |
BC
Broadfin Capital
New York
|
+$6.97M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.79M |
| 4 |
AC
Armistice Capital
New York
|
+$6.3M |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$2.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIG
Mariner Investment Group
Harrison,
New York
|
-$763K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$277K |
| 3 |
FMA
FNY Managed Accounts
New York
|
-$201K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$148K |
| 5 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$101K |
ATRS Hedge Fund Activity: Q2 2015 in Review
88 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q2 2015, worth a combined $143M — up 13% from $127M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ATRS positions and 7 closed out — a net gain of 8 holders — while 49 added to existing stakes and 13 trimmed.
The largest buyer was Deerfield Management, adding an estimated $15.3M. The largest seller was Mariner Investment Group, exiting entirely with an estimated $763K sold.
- 88 institutional investors held Antares Pharma, Inc. (ATRS) as of Q2 2015, up from 81 in Q1 2015.
- Funds reported $143M of Antares Pharma, Inc. stock for Q2 2015, up 13% quarter-over-quarter.
- 15 funds opened new Antares Pharma, Inc. positions in Q2 2015 and 7 closed out, a net change of +8 holders.
- The largest Antares Pharma, Inc. buyer in Q2 2015 was Deerfield Management, an estimated $15.3M added.
- The largest Antares Pharma, Inc. seller in Q2 2015 was Mariner Investment Group, an estimated $763K sold.
Based on aggregated 13F filings for Q2 2015.